ストックスクリーナーアプリを入手
7.83
1.01%
-0.08
前日終値:
$7.91
開ける：
$7.9
24時間の取引高:
404.14K
Relative Volume:
0.40
時価総額：
$386.98M
収益：
$89.04M
当期純損益:
$-241.08M
株価収益率:
-1.4886
EPS:
-5.26
ネットキャッシュフロー:
$-194.72M
1週間 パフォーマンス:
-4.98%
1か月 パフォーマンス:
+18.64%
6か月 パフォーマンス:
-27.50%
1年 パフォーマンス:
-62.84%
1日の値動き範囲:
$7.6828
$7.96
1週間の範囲:
$7.6828
$8.82
52週間の値動き範囲:
$5.66
$21.57
Regenxbio Inc Stock (RGNX) Company Profile
RGNX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
7.83 | 386.98M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-11 | ダウングレード | Goldman | Buy → Neutral |
| 2025-02-07 | 再開されました | Raymond James | Outperform |
| 2024-11-15 | 再開されました | Morgan Stanley | Overweight |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-06-07 | 開始されました | Goldman | Buy |
| 2024-03-11 | 開始されました | H.C. Wainwright | Buy |
| 2024-03-08 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | 再開されました | Raymond James | Outperform |
| 2023-11-01 | 開始されました | Stifel | Buy |
| 2023-06-02 | 開始されました | Robert W. Baird | Outperform |
| 2022-06-23 | 開始されました | Berenberg | Buy |
| 2021-12-15 | 開始されました | Wedbush | Neutral |
| 2021-10-19 | 再開されました | Morgan Stanley | Overweight |
| 2021-01-06 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | 開始されました | UBS | Buy |
| 2020-06-25 | 再開されました | BofA/Merrill | Buy |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | アップグレード | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-06-14 | 再開されました | Raymond James | Outperform |
| 2019-06-05 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-02-25 | アップグレード | Evercore ISI | In-line → Outperform |
| 2019-02-05 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-11-08 | 繰り返されました | BofA/Merrill | Neutral |
| 2018-08-08 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-07-23 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-05-09 | 繰り返されました | Barclays | Overweight |
| 2018-04-09 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-03-12 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2018-02-13 | 開始されました | Mizuho | Neutral |
| 2017-11-09 | 再開されました | Morgan Stanley | Overweight |
すべてを表示
Regenxbio Inc (RGNX) 最新ニュース
5 Reasons To Buy Regenxbio Right Now (NASDAQ:RGNX) - Seeking Alpha
REGENXBIO partners with Nippon Shinyaku for MPS therapies - MSN
Regenxbio’s Triple Threat: Partnered Programs, DMD Progress And In-House Manufacturing - In Vivo
RegenXBio Positioned Favorably Amid Competitor Safety Concerns, Justifying Buy Rating - TipRanks
REGENXBIO’s DMD Gene Therapy RGX-202 Generates Microdystrophin Expression in Additional Patients Treated in Phase 1/2 Trial - CGTLive™
Regenxbio Rises After Duchenne Update And Sarepta Safety Scare - News & Insights
Sarepta safety update on Elevidys boosts Regenxbio, hurts Solid Bio - MSN
Regenxbio’s RGX-202 continues to show promise in DMD - The Pharma Letter
Regenxbio’s DMD gene therapy drives 122.3% biomarker uptick in three-year-old - Clinical Trials Arena
Regenxbio stock target raised to $29 at Raymond James By Investing.com - Investing.com Canada
REGENXBIO reports promising gene therapy trial results By Investing.com - Investing.com South Africa
Baird maintains Regenxbio stock outperform rating, $39 target By Investing.com - Investing.com South Africa
Baird maintains Regenxbio stock outperform rating, $39 target - Investing.com
Regenxbio stock target raised to $29 at Raymond James - Investing.com India
Regenxbio up 4% following additional data on Duchenne gene therapy asset - MSN
Regenxbio Touts Positive Biomarker Data From Duchenne Muscular Dystrophy Gene Therapy Trial - Benzinga India
Regenxbio Says New Data Support Potential Gene Therapy for Duchenne Muscular Dystrophy - Marketscreener.com
REGENXBIO reports promising gene therapy trial results - Investing.com India
REGENXBIO: New Interim Data Reinforces Potential Of RGX-202Quick Facts - Nasdaq
Breakthrough: REGENXBIO DMD Gene Therapy Achieves Unprecedented 122% Protein Expression - StockTitan
Regenxbio stock up, Solid Bio down post Sarepta update (RGNX) - Seeking Alpha
Regenxbio at UBS Virtual CNS Day: Gene Therapy Advancements - Investing.com
Regenxbio at UBS Virtual CNS Day: Gene Therapy Advancements By Investing.com - Investing.com Canada
H.C. Wainwright cuts Regenxbio stock target to $34, maintains buy By Investing.com - Investing.com Philippines
REGENXBIO Inc. (NASDAQ:RGNX) Is About To Turn The Corner - Yahoo Finance
H.C. Wainwright cuts Regenxbio stock target to $34, maintains buy - Investing.com India
Regenxbio completes its BLA filing for first potential gene therapy for MPS II - The Pharma Letter
REGENXBIO Earnings Call Highlights Strategic Progress - TipRanks
Earnings call transcript: Regenxbio Q4 2024 beats EPS forecast, stock surges - Investing.com Australia
Stifel maintains Buy on Regenxbio stock, $40 target By Investing.com - Investing.com South Africa
Stifel maintains Buy on Regenxbio stock, $40 target - Investing.com India
A Glimpse Into The Expert Outlook On Regenxbio Through 5 Analysts - Benzinga
Regenxbio Inc earnings beat by $0.12, revenue fell short of estimates - Investing.com Australia
Regenxbio Inc (RGNX) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Resilience - Yahoo Canada Finance
REGENXBIO Reports Progress in Gene Therapy Pipeline - TipRanks
Regenxbio Q4 License & Royalty Revenue USD 21.214 Million -March 13, 2025 at 05:37 pm EDT - Marketscreener.com
Regenxbio Inc (RGNX) Q4 2024 Earnings: EPS Beats Estimates at -$1.01, Revenue Misses at $21.2 Million - GuruFocus.com
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Regenxbio: Q4 Earnings Snapshot - San Antonio Express-News
Regenxbio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
REGENXBIO Earnings Results: $RGNX Reports Quarterly Earnings - Nasdaq
REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates - PR Newswire
Regenxbio Inc (RGNX) 財務データ
収益
当期純利益
現金流量
EPS
Regenxbio Inc (RGNX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| KARABELAS ARGERIS N | Director |
Oct 01 '24 |
Option Exercise |
3.76 |
10,000 |
37,600 |
21,286 |
| KARABELAS ARGERIS N | Director |
Oct 01 '24 |
Sale |
10.11 |
10,000 |
101,052 |
11,286 |
| KARABELAS ARGERIS N | Director |
Sep 03 '24 |
Option Exercise |
3.76 |
10,000 |
37,600 |
21,286 |
| KARABELAS ARGERIS N | Director |
Sep 03 '24 |
Sale |
11.56 |
10,000 |
115,588 |
11,286 |
| Mills Kenneth T. | Director |
Aug 08 '24 |
Option Exercise |
0.85 |
36,316 |
30,869 |
444,351 |
| KARABELAS ARGERIS N | Director |
Aug 01 '24 |
Option Exercise |
3.85 |
10,100 |
38,874 |
21,386 |
| KARABELAS ARGERIS N | Director |
Aug 01 '24 |
Sale |
13.51 |
10,100 |
136,454 |
11,286 |
| Simpson Curran | Chief Executive Officer |
Aug 01 '24 |
Sale |
15.00 |
100 |
1,500 |
170,037 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):